Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.


Genmab's Post-ASH Seminar

Genmab hosted its Post-ASH Seminar on December 9, which provided an update on the Company's progress during 2014, including data from studies with the Company's antibodies presented at the 2014 American Society of Hematology (ASH) Annual Meeting, progress with Genmab's proprietary technologies and expected performance milestones for 2015. Click here to view a replay of the webcast.  To view the slides click here.  

Third Quarter 2014 Financial Results

Genmab reported its Third Quarter 2014 financial results and held a conference call on November 5. Click the following links to access the archived call: Listen to the webcast/podcast; download the slide presentation.

Genmab Opens Doors to Innovation

Genmab is inviting researchers in academia and industry to experience the full power of the DuoBody® platform for bispecific antibody research and drug development. Explore the possibilities via our recently published Perspective in the journal mAbs and the renewed Open Innovation section on

Latest news


  • At the heart of Genmab is a deep desire to improve the quality of life for cancer patients.
  • Click here to watch our video about our fight against cancer.


Stock Price as of 01/29/2015 12:00 AM (CET)

  • Share Price DKK 441.30
  • Change (in DKK) -1.70
  • Volume 140476

Stock Information